OSR Holdings (OSRH) Stock: CEO Appointment Sparks 24.42% Jump in Stock Price

Table of Contents

TLDR:

OSR Holdings sees 24.42% jump as Dr. Niethammer becomes Vaximm CEO.

OSR Holdings stock surges after Vaximm CEO announcement by Dr. Niethammer.

Dr. Andreas Niethammer named Vaximm CEO, triggering OSR Holdings stock spike.

Vaximm CEO change boosts OSR Holdings stock with new cancer immunotherapy plans.
OSR Holdings rises 24.42% as Dr. Niethammer takes the helm at Vaximm AG.

OSR Holdings, Inc. (NASDAQ: OSRH) experienced a notable surge in its stock price, rising by 24.42% to $0.5669 following an early morning spike.

OSRH Stock Card
OSR Holdings, Inc., OSRH

The price briefly topped $0.60 before retracing back to its current level, indicating volatility in market sentiment. This surge coincided with the company’s announcement that Dr. Andreas Niethammer will become the new CEO of its subsidiary, Vaximm AG, effective December 1, 2025.

Dr. Niethammer Takes Leadership at Vaximm AG

Dr. Andreas Niethammer’s appointment as CEO of Vaximm AG marks a significant development for both Vaximm and OSR Holdings. Dr. Niethammer, a renowned oncology expert, is Vaximm’s scientific co-founder and has been instrumental in the company’s progress. Vaximm, a Swiss-German biotech company, focuses on oral T-cell immunotherapy, including its lead candidate VXM01, which has advanced into clinical trials for pancreatic cancer and glioblastoma.

Under Dr. Niethammer’s leadership, Vaximm will prioritize the integration of its anti-angiogenic immune activation platform with viral oncolysis technologies. These technologies have already demonstrated clinical proof-of-concept in a U.S. FDA Phase 2a study, targeting renal cell carcinoma and other advanced solid tumors. Vaximm plans to announce a strategic collaboration soon, aimed at developing next-generation immuno-oncology therapies.

Vaximm’s Focus on Immuno-Oncology and Future Collaborations

Dr. Niethammer expressed excitement about Vaximm’s next phase, where the company will combine its oral vaccination platform with potent oncolytic and immune-modulating technologies. The goal is to achieve more durable and systemic antitumor responses while maintaining excellent safety profiles. Vaximm’s innovative approach is expected to be a key factor in the company’s success in advancing cancer therapies.

Peter Hwang, CEO of OSR Holdings, praised Dr. Niethammer for his vision and deep clinical development experience. Hwang emphasized that Dr. Niethammer’s appointment represents a natural progression for Vaximm, setting the stage for further scientific breakthroughs and strategic partnerships. The appointment underscores OSR Holdings’ commitment to fostering scientific innovation through leadership at its subsidiaries.